Compare Expeditors International of Wshngtn Inc (EXPD) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Inovio Pharmaceuticals Inc — how do they compare? Expeditors International of Wshngtn Inc trades at $181.87 (market cap $23.24B), while Inovio Pharmaceuticals Inc trades at $1.16 (market cap $96.26M). The key difference: Expeditors International of Wshngtn Inc is far larger — about 241.4× Inovio Pharmaceuticals Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.91% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| EXPD | INO | |
|---|---|---|
Market Cap | $23.24B | $96.26M |
Sector | Industrials | Health |
52-Week High | $178.22 | $2.87 |
52-Week Low | $111.37 | $1.05 |
Enterprise Value | $22.49B | $67.27M |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expeditors International (EXPD) trades at $178.22, up 1.55% on the day, and has consistently beaten earnings estimates in recent quarters. The stock shows strong technical momentum with a bullish moving average signal, though oscillators suggest overbought conditions. Fundamentally, the company maintains robust profitability with a 7.48% net margin and 36.59% ROE, supported by positive operating cash flow of $1.01B in 2025. Recent news highlights the stock's inclusion on strong buy lists and its resilience in the transportation services sector.
The outlook is mixed with strong fundamentals and positive earnings momentum offset by a cautious analyst consensus and elevated valuation multiples. The primary opportunity lies in continued execution and e-commerce demand driving intermodal services, while risks include industry freight downturns, economic uncertainties, and the stock trading above the consensus price target of $161.50.
INO trades at $1.16 with no recent price movement, reflecting its speculative biotech profile. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Technical indicators are bearish overall, though some oscillators suggest potential oversold conditions. Recent news highlights the critical FDA decision for INO-3107 in October 2026 as the primary near-term catalyst.
The investment case hinges entirely on regulatory approval of INO-3107, with analysts maintaining a cautiously optimistic stance (53% buy ratings). However, substantial financial risks persist including negative cash flow, high burn rate, and shareholder litigation. Successful FDA approval could drive significant upside, while rejection would likely exacerbate financial pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
